1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BB9A47FAC48372F6002586E00037C38E
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/medical-affairs-2025-where-are-we-going-how-do-we-get-there
18
19
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Medical Affairs Excellence

Medical Affairs 2025: Where Are We Going? How Do We Get There?

ID: POP-336


Features:

6 Info Graphics

28 Data Graphics

460+ Metrics

8 Narratives


Pages: 44


Published: 2021


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
The last decade has seen Medical Affairs evolve from a support function to what many view as the third leadership pillar in biopharma. While the pace of change has significantly altered the healthcare landscape in the last few years, the Covid-19 pandemic has triggered a tsunami of rapid technology and role changes for Medical Affairs in particular.

While many of the fundamental trends will continue, the Medical Affairs function will also see new priorities and growth levels as we approach 2025.

Best Practices, LLC undertook this research to explore a four-year future horizon for Medical Affairs: What will the Medical Affairs organization look like in 2025? How will Medical Affairs leaders get there? The research examines evolving roles, stakeholder priorities, tools, technologies, capabilities, structures, rates of change, and top value fronts for this critical biopharma function.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Medical Device; Diagnostic; Health Care; Medical; Consulting; Consumer Products; Clinical Research; Laboratories


Companies Profiled:
AbbVie; Adamas Pharmaceuticals; Alkermes; Apellis Pharmaceuticals; ASC Therapeutics; Astellas; AstraZeneca; Aziyo Biologics; Inc.; Baxter Healthcare; BioMarin; bioMerieux; Boehringer Ingelheim; Castle Creek Biosciences; Cipla; Clovis Oncology; Eisai; Eli Lilly; EMD Serono; Gama PharMed Solutions Limited; Glenmark; Gossamer Bio; Greenwich Biosciences; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson; Leica Biosystems; LEO Pharma; Lundbeck; Maxwell Clinic; MEDiSTRAVA; Melinta Therapeutics; Inc; Merck; Milestone Pharmaceuticals; Natera; NexGen Pharma; Novartis; Novavax; Novo Nordisk; Orion Pharmaceuticals; Pfizer; Partner Therapeutics (PTx); Regeneron; Roche; Sandoz; Sanofi; Sanofi Genzyme; Santen; Servier; Sunovion; Takeda Pharmaceuticals; Terumo Corporation; Teva Pharmaceutical Industries Ltd; United Therapeutics; Virbac; Zoetis Inc.

Study Snapshot

Best Practices, LLC developed a benchmark protocol that examines current and future Medical operations, capabilities, and performance. The study analysis engaged 74 executives from 57 leading life sciences companies. Chief Medical Officers and Medical Directors represent nearly 80% of the leaders who reflected on current Medical trends and future directions in this study.

Key topics covered in this report include:

  • Formula for Medical Affairs Excellence
  • Medical Affairs Priorities for 2025
  • Future Development in Medical Affairs
  • Medical’s Strategic Roles, Capabilities and Stakeholder Involvement
  • Medical Affairs Hybrid Workplace and Digital Transformation
  • Evidence Generation in 2025
  • Key Medical Affairs Responsibilities by 2025
  • Medical Affairs Value Communication
  • Optimizing Structure of Medical Affairs in 2025

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Stakeholder Involvement: HCPs, Thought Leaders and Guideline Orgs. will remain key stakeholders. Payers, Advocacy Groups, Govt. Agencies, ACO/ IDNs, Pathway Vendors, Large employer groups & specialty pharmacies are high-growth areas headed towards 2025.
  • Digital Transformation: Post COVID, the majority of companies will use hybrid medical approaches for various group and functional roles. Digital technologies will extend reach, function and productivity across multiple groups within medical.
  • Evolution of RWE: Real world evidence is accelerating through technological advancements, greater payer focus, expanding MSL roles, and upgrading patient management pathways.

Table of Contents

Sr. No.
Topic
Slide No.
I.
Research Overview, Methodology & Participating CompaniesPg. 3
II.
Executive SummaryPg. 4-5
III.
Medical Affairs Excellence: Moving to the Next Level by 2025Pg. 6-9
IV.
Medical’s Strategic Roles, Capabilities & Stakeholder InvolvementPg. 10-18
V.
Hybrid Workplace & Digital TransformationPg. 19-22
VI.
Evidence, Insights, Value and StructurePg. 23-30
VII.
Benchmark Class ProfilePg. 31-33
VIII.
Detailed Benchmark Study DataPg. 34-43
IX.
About Best Practices, LLCPg. 44

    List of Charts & Exhibits

    I. Medical Affairs Excellence: Moving to the Next Level by 2025

    • Formula for excellence: Medical Affairs 2025 evolves and elevates five operational variables driving performance
    • Seven most important ranked priorities for Medical Affairs to achieve next level
    • Future Development in Medical Affairs

    II. Medical’s Strategic Roles, Capabilities & Stakeholder Involvement

    • Current and future state of Medical Affairs’ leadership and support role
    • Important foundational Medical Affairs elements
    • External stakeholder groups with whom Medical Affairs works currently
    • External stakeholder groups with whom Medical Affairs will work in future
    • Importance and effectiveness of different external groups to the work conducted within the Medical Affairs organization
    • Importance and effectiveness of different external groups to the work conducted within Medical Affairs by 2025
    • Frequency of engagement of various Medical sub-functions with different external groups
    • Anticipated frequency of engagement of various Medical sub-functions with different external groups by 2025

    III. Hybrid Workplace & Digital Transformation

    • Whether the concept of an office-based Medical Affairs employee is a thing of the past in the post-COVID era or not
    • Remote vs. office-based Medical Affairs post-COVID
    • Types of virtual capabilities being used / explored by benchmark organizations since the start of the COVID-19 pandemic

    IV. Evidence, Insights, Value and Structure

    • Top Medical groups with greater importance in 2025, Top Medical groups with lesser importance in 2025
    • Evolution of evidence generation in 2025
    • Top roles undertaken by Medical Affairs to showcase value
    • Key responsibilities for Medical Affairs now and by 2025
    • Medical Affairs value communication
    • Optimizing structure of Medical Affairs in 2025
    • Medical group consolidation envisioned by leadership across key areas